The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review.
about
Prostate cancer: ESMO Consensus Conference Guidelines 2012Risk calculators and updated tools to select and plan a repeat biopsy for prostate cancer detectionThe relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative GroupExternal Evaluation of a Novel Prostate Cancer Risk Calculator (ProstateCheck) Based on Data from the Swiss Arm of the ERSPC.Multivariate model for predicting semen cryopreservation outcomes in a human sperm bank.Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.Barriers and facilitators to digital rectal examination screening among African-American and African-Caribbean menNatriuretic Peptides and Assessment of Cardiovascular Disease Risk in Asymptomatic Persons.Alzheimer disease identification using amyloid imaging and reserve variables: proof of concept.Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.Developing a follow-up strategy for patients with PSA ranging from 4 to 10 ng/ml via a new model to reduce unnecessary prostate biopsiesProstate cancer in young men: an important clinical entity.Nonlinear modeling was applied thoughtfully for risk prediction: the Prostate Biopsy Collaborative Group.DNA methylation of GSTP1 in human prostate tissues: pyrosequencing analysisCommon genetic variants in prostate cancer risk prediction--results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3)Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group.External validation of extended prostate biopsy nomogram.A nomogram based on age, prostate-specific antigen level, prostate volume and digital rectal examination for predicting risk of prostate cancer.Absence of Bladder Outlet Obstruction Is an Independent Risk Factor for Prostate Cancer in Men Undergoing Prostate Biopsy.A prostate biopsy strategy based on a new clinical nomogram reduces the number of biopsy cores required in high-risk patients.Should prostate-specific antigen screening be offered to asymptomatic men?Risk-based prostate cancer screening.Risk stratification in prostate cancer screening.Recommendations from the EGAPP Working Group: does PCA3 testing for the diagnosis and management of prostate cancer improve patient health outcomes?The development of nomograms for stratification of men at risk of prostate cancer prior to prostate biopsy.Nomogram to predict prostate cancer diagnosis on primary transrectal ultrasound-guided prostate biopsy in a contemporary series.Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis.Can the prostate risk calculator based on Western population be applied to Asian population?Risk stratification of prostate cancer: integrating multiparametric MRI, nomograms and biomarkers.A nomogram for prediction of prostate cancer on multi-core biopsy using age, serum prostate-specific antigen, prostate volume and digital rectal examination in Singapore.Could Magnetic Resonance Imaging Help to Identify the Presence of Prostate Cancer Before Initial Biopsy? The Development of Nomogram Predicting the Outcomes of Prostate Biopsy in the Chinese Population.Internal validation of an artificial neural network for prostate biopsy outcome.A direct comparison of the diagnostic accuracy of three prostate cancer nomograms designed to predict the likelihood of a positive initial transrectal biopsy.Nomogram using transrectal ultrasound-derived information predicting the detection of high grade prostate cancer on initial biopsy.Development, validation and comparison of two nomograms predicting prostate cancer at initial 12-core biopsy.External validation of an artificial neural network and two nomograms for prostate cancer detection.Multiparametric Magnetic Resonance Imaging for Active Surveillance of Prostate CancerCan a supervised algorithmic assessment of men for prostate cancer improve the quality of care? A retrospective evaluation of a prostate assessment pathway in Saskatchewan.Yonsei nomogram to predict lymph node invasion in Asian men with prostate cancer during robotic era.Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial*.
P2860
Q27022847-EE1D073E-2DE9-467C-93A5-2965345495E3Q27027085-311E6CE0-A2FD-41EE-AACA-7A018BCFA486Q28749313-BDE2B52A-AC08-496D-B002-097A77F1BE64Q31096808-737AB4A1-0256-4D02-9795-035F21174EB0Q33458147-9926E6A1-A421-48FE-BEBA-4E73D4E3FFD6Q33545711-8C9F30FE-6098-4478-A961-A0EA0EEB0964Q33866618-375BF09D-2EDD-461C-A0CD-D48FE2BFD70EQ33948944-829E6C77-92F5-42CE-8DA6-11F3464C1234Q34004313-C3EADFD7-C8E0-4B5D-89E2-20155BFE8CB5Q34130128-02299ED3-F3A3-4556-ACA6-4AF487EA60E6Q34276126-C3A4B00D-C165-4563-A9D3-386925D60D50Q34314644-54E968DD-9FF9-48A2-AA0B-CE2E108CCD8DQ35760036-24D187E0-AC0E-457A-BD91-7B4D5F7C56B3Q35852010-5931779E-9514-4215-AD57-39870C3DA6A9Q35868793-A483B47C-70D8-42CC-936E-6C2876FEEA4EQ35875135-E3974422-3EC5-4607-8201-E691AB927220Q35921555-43FC6899-594F-4EC1-9BF7-8465BA4FFACAQ37084150-EFC1CF27-C106-416E-9C35-CC947B0EBB74Q37206050-71740A17-480A-4092-9850-A6F20813FACFQ37485613-87F82E47-6262-4643-A331-1FDD999520B5Q37774352-80216A13-7BD6-4FC9-BE41-533338E75307Q37963657-B980BF42-5BD7-4A05-8C3F-3C966A6EB3FAQ38068114-2A97310A-D045-492F-BCD5-5B5BA8CD530FQ38144712-4C688EED-65DC-4056-ACCD-70046961B2CAQ38165242-5AB60C0B-FCD5-4916-AA0D-6B09BB8BF2B0Q38219393-B8622AE1-289B-4546-8506-8B3C2F685261Q38268839-1E5D7826-4500-46D0-874D-128DD38C0881Q38471448-B46FEDD2-250C-4ED7-B2D4-6A1B6A0D5C49Q38843182-9AAFC2BE-CE30-43C3-B021-9882F7BF5952Q39377009-5DB5584E-5272-4527-957D-7E68A13B86CFQ39554008-B0C7B455-30CF-4B3E-AA57-BBA284229EDBQ39908377-E912BD9F-22B6-4BC1-A622-8D6D45B6B849Q40014386-B5EF1E80-7691-46D6-BA33-C5BD2CC477D3Q40149911-C8678F10-70F4-4485-A152-ED3EC2D33197Q40181136-1A8E5EA5-C331-4783-B599-287BA7776BBBQ41832537-2B020D9E-E66C-4CBB-AD65-263C39B549E4Q42374568-A60FE6D8-65D7-4C1E-B97E-98E2FF4DCBDBQ47554663-A69409EB-A330-4846-874C-9DE8ADA5DB7FQ51167329-791263AF-72FF-4D90-92BF-2C6D1A698154Q51312747-BF1AC788-0DF4-41C9-BCBF-5910624FB0A6
P2860
The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
The comparability of models fo ...... en alone: a systematic review.
@ast
The comparability of models fo ...... en alone: a systematic review.
@en
The comparability of models fo ...... en alone: a systematic review.
@nl
type
label
The comparability of models fo ...... en alone: a systematic review.
@ast
The comparability of models fo ...... en alone: a systematic review.
@en
The comparability of models fo ...... en alone: a systematic review.
@nl
prefLabel
The comparability of models fo ...... en alone: a systematic review.
@ast
The comparability of models fo ...... en alone: a systematic review.
@en
The comparability of models fo ...... en alone: a systematic review.
@nl
P1433
P1476
The comparability of models fo ...... en alone: a systematic review.
@en
P2093
Fritz Schröder
Michael W Kattan
P304
P356
10.1016/J.EURURO.2008.05.022
P407
P577
2008-05-22T00:00:00Z